Johnson & Johnson
NYSE: JNJ
$145.85
+$0.58 (+0.4%)
Closing Price on December 24, 2024
JNJ Articles
Goldman Sachs may have the best strategy for investors for 2020. Here are five stocks that look like great ideas now for investors looking to mold such a plan.
Published:
Last Updated:
Johnson & Johnson has found itself involved in more controversy than the company would prefer to see. But it seems that not even bad news lasts forever.
Published:
Last Updated:
Credit Suisse and Merrill Lynch made calls in the biotech and pharmaceutical space last week, ahead of coming earnings reports.
Published:
Last Updated:
Wednesday's top analyst upgrades, downgrades and initiations included Adobe, Alibaba, Amazon.com, AT&T, Comcast, Delphi Technologies, DocuSign, Johnson & Johnson, JPMorgan, T-Mobile, Verizon...
Published:
Last Updated:
Johnson & Johnson reported better than expected quarterly results before the markets opened on Tuesday.
Published:
Last Updated:
Johnson & Johnson is scheduled to report its most recent quarterly results before the markets open on Tuesday, and analysts' expectations are mild overall.
Published:
Last Updated:
Seven of the 30 Dow Jones industrial average components are scheduled to report their latest quarterly reports this week.
Published:
Last Updated:
Friday's top analyst upgrades, downgrades and initiations included Apple, Canopy Growth, CrowdStrike, Delta Air Lines, Johnson & Johnson, Rio Tinto, Roku, Square, Tilray and Twilio.
Published:
Last Updated:
Johnson & Johnson shares dropped on Wednesday following the announcement that a jury has awarded $8 billion in damages to a man accusing the drugmaker of failing to warn about the side effects of...
Published:
Last Updated:
One analyst issued a fairly bullish report in response to Johnson & Johnson's announcement of a $10 million settlement with two Ohio counties ahead of an upcoming opioid trial.
Published:
Last Updated:
Five drugmakers are considering a proposal that would have them contribute to a trust established as part of the bankruptcy settlement by Purdue Pharmaceuticals and be released from liability in the...
Published:
Last Updated:
The last thing investors want is a value trap loser that stays stagnant, but all these top companies have solid long-term prospects.
Published:
Last Updated:
As, when and if ESG themes continue to gain in popularity, imagine what could happen to some of the top-ranked ESG companies. Imagine also what could happen to some of the companies that are...
Published:
Last Updated:
Johnson & Johnson is trading higher on the news, but some smaller public companies tied into the opioid crisis are taking it on the chin.
Published:
Last Updated:
24/7 Wall St. has evaluated all pharmaceutical and biotech companies that pay dividend yields above 2% based on their current prices.
Published:
Last Updated: